Q4 EPS Estimate for Bio-Rad Laboratories Boosted by Analyst

Bio-Rad Laboratories, Inc. (NYSE:BIO) – Investment analysts at Zacks Research lifted their Q4 2024 EPS estimates for shares of Bio-Rad Laboratories in a report released on Thursday, February 6th. Zacks Research analyst R. Department now forecasts that the medical research company will post earnings per share of $2.87 for the quarter, up from their previous estimate of $2.86. The consensus estimate for Bio-Rad Laboratories’ current full-year earnings is $10.33 per share. Zacks Research also issued estimates for Bio-Rad Laboratories’ Q2 2025 earnings at $3.16 EPS.

A number of other analysts also recently issued reports on the stock. Royal Bank of Canada reiterated an “outperform” rating and issued a $481.00 price objective on shares of Bio-Rad Laboratories in a report on Tuesday, January 14th. StockNews.com raised shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research report on Friday, November 1st. Finally, Citigroup boosted their target price on shares of Bio-Rad Laboratories from $400.00 to $450.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $394.20.

Bio-Rad Laboratories Stock Down 4.6 %

Bio-Rad Laboratories stock opened at $326.36 on Monday. The company’s 50 day simple moving average is $340.91 and its 200 day simple moving average is $336.95. Bio-Rad Laboratories has a fifty-two week low of $262.12 and a fifty-two week high of $387.99. The firm has a market capitalization of $9.14 billion, a price-to-earnings ratio of -11.94 and a beta of 0.90. The company has a debt-to-equity ratio of 0.16, a current ratio of 6.14 and a quick ratio of 4.52.

Institutional Investors Weigh In On Bio-Rad Laboratories

Several institutional investors and hedge funds have recently bought and sold shares of BIO. Wealthfront Advisers LLC purchased a new stake in Bio-Rad Laboratories in the 4th quarter worth about $342,686,000. Van ECK Associates Corp boosted its position in shares of Bio-Rad Laboratories by 97.8% during the 3rd quarter. Van ECK Associates Corp now owns 1,303,752 shares of the medical research company’s stock valued at $436,861,000 after acquiring an additional 644,530 shares during the last quarter. Point72 Asset Management L.P. bought a new stake in Bio-Rad Laboratories in the 3rd quarter worth approximately $83,681,000. Wedge Capital Management L L P NC bought a new stake in Bio-Rad Laboratories in the 4th quarter worth approximately $28,740,000. Finally, Mawer Investment Management Ltd. lifted its position in Bio-Rad Laboratories by 63.0% in the 3rd quarter. Mawer Investment Management Ltd. now owns 217,885 shares of the medical research company’s stock worth $72,900,000 after buying an additional 84,237 shares during the last quarter. Institutional investors own 65.24% of the company’s stock.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.